antigen-presenting cell

(redirected from Antigen presenting cell)

antigen-presenting cell

a cell that can break down protein antigens into peptides and present the peptides, in conjunction with major HLA complex class II molecules, on the cell surface, where they can interact with T cell receptors. Macrophages are one type of antigen-presenting cell.

antigen-presenting cell

Abbreviation: APC
A cell that breaks down antigens and displays their fragments on surface receptors next to major histocompatibility complex molecules. This presentation is necessary for some T lymphocytes that are unable to recognize soluble antigens. Macrophages are the primary antigen-presenting cells, but B cells and dendritic cells also can act as APCs.
See: T cell; macrophage processing cell
See also: cell

antigen-presenting cell

A cell, such as a macrophage, a B cell or a dendritic cell, that presents processed antigenic peptides and MHC class II molecules to the T cell receptor on CD4 T cells.
References in periodicals archive ?
The recognition of bacterial and viral products by Toll-like receptors on cells of the innate immune system also results in NF-KappaB induction, leading to the production of proinflammatory cytokines and the activation of Antigen Presenting Cell for T-Cell costimulation in the adaptive immune response.
Abatacept (Orencia[R], Bristol-Myers Squibb) is a selective T-cell costimulation modulator that blocks the activation of T cells by interrupting the interaction between the CD28 ligand on the T cell and the CD80/86 ligand on the antigen presenting cell (Fig.
and the international Ludwig Institute for Cancer Research (LICR) have announced a multi-year clinical research collaboration focusing on a series of tumor-associated antigens (TAAs) for use in Celldex's Antigen Presenting Cell (APC) Targeting Technology.
IMP321, a first-in-class Antigen Presenting Cell (APC) activator based on the immune checkpoint LAG-3, represents one of the first proposed active immunotherapy drugs in which the patient's own immune system is harnessed to respond to tumour antigenic debris created by chemotherapy.
IMP321, which is a soluble form of LAG-3, is an antigen presenting cell activator that induces T cell immunostimulation for cancer chemoimmunotherapy.
The expanded peptide-specific regulatory cells shut down the autoimmune attack by preventing aggressive autoimmune cells from being stimulated by either the peptide contained in the vaccine or by any other type 1 diabetes autoantigen presented simultaneously on the same antigen presenting cell.
The method involves the loading of an antigen presenting cell with at least one tumor associated T-cell epitope attached to an immunoglobulin backbone to form an Ig-peptide molecule ("IgNP") followed by administration the IgNP in conjunction with MCT-465, a dsRNA TLR agonist adjuvant therapeutic.
Recently, MultiCell filed the patent application entitled, "Methods for Tumor Control and Treatment by Loading an Antigen Presenting Cell," which covers the use of MultiCell's proprietary dsRNA and Toll-like receptor (TLR) technology platform to combat malignant tumors in human patients.
In an newsletter article released today, SmallCapInsights addresses MultiCell's most recent patent announcementCo"Methods for Tumor Control and Treatment by Loading an Antigen Presenting Cell," and provides investors with background on the Company and opinion on its progress and potential.
The patent filing, "Methods for Tumor Control and Treatment by Loading an Antigen Presenting Cell," covers the use of MultiCell's proprietary dsRNA and Toll-like receptor (TLR) technology platform to combat malignant tumors in human patients.
APX005M is a novel, humanised investigational monoclonal antibody designed to overcome the systemic immune suppression that typically affects cancer patients through activation of CD40, a co-stimulatory receptor on the antigen presenting cells that is essential for activating both innate and adaptive immunity.